Lixte Biotechnology Holdings Total Current Liabilities

Lixte Biotechnology Holdings (LIXT) currently reports a total current liabilities of $1.5M as of June 2026. That compares with $540K in the prior-year period — up 179.3% year over year. Use the charts on this page to explore Lixte Biotechnology Holdings's total current liabilities history and peer comparisons.

Lixte Biotechnology Holdings's total current liabilities increased from $540K to $1.5M — a 179.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lixte Biotechnology Holdings reported $1.5M in total current liabilities as of June 2026. That compares with $540K in the prior-year period — up 179.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $1.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lixte Biotechnology Holdings, and consider following LIXT for alerts when major investors trade the stock.

Lixte Biotechnology Holdings is classified in the Healthcare sector. On total current liabilities, it currently shows $1.5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LIXT with unrelated industries.